Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
StockNews.AI · 494 days
AI Summary
Aptevo announces a 1-for-37 reverse stock split to comply with Nasdaq listing. Effective date for the reverse split is December 3, 2024, market open December 4. Outstanding shares will reduce from approximately 18.5 million to 0.5 million. Split aims to maintain minimum bid price requirement of $1.00 per share. Stockholder approval occurred on October 25, 2024, finalizing the reverse split.
Sentiment Rationale
A reverse stock split can boost APVO's market perception and attract investors, similar to previous instances in biotech.
Trading Thesis
Market reaction to the reverse split will likely impact APVO's price shortly after implementation.
Market-Moving
- Aptevo announces a 1-for-37 reverse stock split to comply with Nasdaq listing.
- Effective date for the reverse split is December 3, 2024, market open December 4.
- Outstanding shares will reduce from approximately 18.5 million to 0.5 million.
Key Facts
- Aptevo announces a 1-for-37 reverse stock split to comply with Nasdaq listing.
- Effective date for the reverse split is December 3, 2024, market open December 4.
- Outstanding shares will reduce from approximately 18.5 million to 0.5 million.
- Split aims to maintain minimum bid price requirement of $1.00 per share.
- Stockholder approval occurred on October 25, 2024, finalizing the reverse split.
Companies Mentioned
- NASDAQ:APVO (NASDAQ:APVO)
Corporate Developments
The reverse split is crucial for compliance and could alter investor sentiment, impacting share price significantly.